Table of Contents

Figure 1 Timeline of infections after Organ Transplant

Figure 2 Timeline of Infections after Hematopoietic Stem Cell Transplant

Figure 3 Immune Reconstitution after Myeloablative Stem Cell Transplant

Table 1 Pre-transplant Infectious Disease Evaluation of the Organ Transplant Candidate

Table 2 Infectious Disease Evaluation of the Hematopoietic Stem Cell Transplant (HSCT) Candidate

Figure 4A Anastomoses and Potential technical complications associated with either a pancreas transplant or kidney transplant

Figure 4B Anastomoses and potential technical complications associated with liver transplantation

Figure 4C Right lobe living donor liver transplant: anastomoses and selected technical complications

Table 3 Right lobe living donor liver transplant: anastomoses and selected technical complications

Table 4 Infections in kidney transplant recipients

Table 5 Infections in pancreas transplant recipients

Table 6 Infections in liver transplant recipients

Table 7 Management of infections in Lung, Heart-Lung, and Heart Transplant Recipients

Table 8 Infections in Intestinal transplant recipients

Table 9A Stepwise Approach to Empiric Antimicrobial Therapy in Febrile Neutropenia

Table 9B Agents for Empiric Antifungal Therapy in Febrile Neutropenics

SECTION B: Specific Pathogens

Table 10A Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

Table 10B Interpretation of Pediatric CMV serology in donors and recipients 18 months

Figure 5A Algorithm for Pre-emptive Therapy of CMV

Table 10C Treatment of CMV Infection and Disease in Solid Organ Transplant Recipients

Figure 5B Suggested algorithm for the management of ganciclovir-resistant CMV infection and disease

Figure 6 Prevention of EBV-related PTLD after Transplant

Table 11A Interpretation of Pediatric EBV serology in donors and recipients 18 months

Table 11B Treatment of PTLD after Transplantation

Table 12 Management of Herpes Simplex Virus (HSV)

Table 13 Management of Varicella Zoster Virus

Table 14 Prevention and Treatment of Human Herpesvirus 6, 7 and 8 Infections in Transplant Recipients

Table 15A Screening, diagnosis and Intervention for PyVAN after renal transplantation

Table 15B Screening for BKV replication in Kidney Transplant Recipients

Table 15C Screening for BKV replication and PyVAN in Non-Kidney Solid Organ Transplant Recipients

Table 15D Treatment of BKV Viremia or PyVAN by modification of maintenance immunosuppression

Table 16A Prevention and treatment of respiratory viral infections after transplantation

Table 16B Prevention and treatment of influenza after transplantation

Figure 7A Treatment of Hand or Plantar (Cutaneous) Warts after Transplantation

Figure 7B Treatment of External Anogenital Warts after Transplantation

Table 17A Hepatitis B Management in HBsAg Positive Recipients

Table 17B Hepatitis B Management in HBcAb Positive, HBsAg Negative, HBsAb Positive or Negative Recipients

Table 18 Hepatitis C Management in Transplant Candidates and Recipients

Table 19A Initial Pre-Transplant Evaluation of Patients with HIV

Table 19B HIV-Patient Selection Criteria for Transplantation

Table 19C Preferred Antiretroviral Drugs in HIV+ Transplant Candidates or Recipients

Table 19D Drug-Drug Interactions and Post-transplant Management in Transplanted Patients with HIV

Table 20 Fungal infection:  Prevention and therapy

Table 21 Treatment of Nocardia Infections

Table 22A Treatment of latent Mycobacterium tuberculosis (TB) infection

Table 22B Treatment of active Mycobacterium tuberculosis infection

Table 23 Treatment of nontuberculous Mycobacterium (NTM) infections

Table 24 Pneumocystis jiroveci pneumonia Prophylaxis and Therapy

Table 25 Suggested therapy of Clostridium difficile colitis after Transplantation

Table 26 Diagnosis and Treatment of Multidrug Resistant Bacteria

Table 27 Management of Selected Parasitic Infections after Transplant

SECTION C: Donor Issues

Table 28 Infectious Disease Evaluation of the Potential Organ Donor

Table 29 Infectious Disease Evaluation of the Potential Hematopoietic Stem Cell Transplant (HSCT) Donor

Table 30A Potential Infections that May be Transmitted from Donor to Recipient

Table 30B Potential Infections that May be Transmitted from Donor to Recipient

Table 31 Estimates of Window Period Length for Serology and Nucleic Acid Testing (NAT)

Table 32 Estimates of residual risk of HIV or HCV when using selected increased risk donor categories

Figure 8 Management of Recipients of Hepatitis B Core Antibody Positive Donor Organ

Table 33 Donor Tuberculosis Issues:  Potential Scenarios and Management

SECTION D: Prevention of Infections after Transplantation

Table 34 Suggested Prophylaxis Regimens in organ transplant recipients

Table 35A Antimicrobial Prophylaxis Regimen for Allogeneic HSCT Recipients

Table 35B Antimicrobial Prophylaxis Regimen for Autologous HSCT Recipients

Table 36 Adult Vaccination Schedule post-Solid Organ Transplantation

Table 37 Adult Vaccination Schedule post-Allogeneic Stem Cell Transplant

Table 38 Immunizations post-pediatric SOT and HSCT

Table 39 Travel-related Recommendations after transplant

Table 40 Safe living strategies for transplant patients

SECTION E: Post-transplant Medications and Drug Interactions

Table 41 Common Immunosuppressive Drugs, Mechanisms of Action, Side Effects, and other Interactions

Table 42 Infectious Risks associated with monoclonal antibodies

Table 43 Drug interactions between antimicrobial agents and common immunosuppressive drugs used in transplantation

Table 44 Antiviral Agents for Adult Transplant Recipients

Table 45 Antifungal Agents in Adult Transplant Recipients

Table 46A Antiviral agents for Pediatric Transplant Recipients

Table 46B Antifungal agents for Pediatric Transplant Recipients ?